Novartis

Clinical Ink announces CentrosHealth Platform captures medical device data

Friday, July 24, 2015

Clinical Ink, a Winston-Salem, N.C.-based provider of eSource solutions for clinical trials, has updated CentrosHealth, a mobile patient engagement platform, to include streamlined connectivity for a wide range of medical devices. Medical device connectivity is powered by the 2net Mobile Platform from Qualcomm Life, a wholly owned subsidiary of Qualcomm Inc. This new platform was developed with cooperation from Novartis and PPD, which also are supporting a pilot clinical study before broad commercial use.

[Read More]

Zogenix expands senior leadership team

Friday, July 10, 2015

Zogenix, a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, has appointed Gail M. Farfel, Ph.D., executive vice president and chief development officer, and Thierry Darcis, M.D., M.B.A., executive vice president and general manager, Europe.

[Read More]

Report: Pharma R&D pipeline value jumps 18% to $493 billion

Wednesday, June 17, 2015

Emerging therapeutic categories and a string of breakthrough drug approvals are powering key drug sales across the U.S. and Europe, fueling a projected 5% increase in global prescription sales over the next five years, according to the EvaluatePharma World Preview 2015, Outlook to 2020 report from life science market intelligence firm Evaluate. With the FDA approving an unprecedented 50 drugs in 2014, eight of which are forecast to have sales of more than $1 billion five years after launch, sustained R&D productivity may finally be within reach.

[Read More]

Report: Innovation trends in treatments for rare diseases and widespread conditions

Wednesday, June 17, 2015

The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine—medicines for rare diseases, vaccines and antibiotics. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

[Read More]

Teva rebuts Mylan chairman’s letter

Wednesday, June 10, 2015

Erez Vigodman, Teva’s president and CEO, has responded to the June 1 letter by Mylan’s executive chairman Robert J. Coury. Vigodman addresses Courey’s accusations about Teva’s hostile takeover of Mylan and the lack of information available to stakeholders.

[Read More]

Perrigo to acquire OTC portfolio from GlaxoSmithKline

Wednesday, June 3, 2015

Perrigo has entered into an agreement to acquire a portfolio of established over-the-counter (OTC) brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK’s commitments to the E.C. and other regulators to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis International. Perrigo will acquire the following assets in an all-cash transaction:

[Read More]

Surface Oncology appoints Detlev Biniszkiewicz CEO

Monday, May 11, 2015

Surface Oncology, a Cambridge, Mass.-based provider of next-generation cancer immunotherapies, has appointed Detlev Biniszkiewicz, Ph.D., president and CEO, effective immediately. Biniszkiewicz brings over 15 years of industry leadership and experience building a transformative pipeline of novel cancer therapies, most recently as the head of the oncology strategy at AstraZeneca.

[Read More]